Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 20/20 | 1.00 |
| ▸ | STK25 | O00506 | 1/20 | 0.84 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.84 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.84 |
| ▸ | GAK | O14976 | 1/20 | 0.84 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.84 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.84 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.84 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.84 |
| ▸ | STK17B | O94768 | 1/20 | 0.84 |
| ▸ | STK10 | O94804 | 1/20 | 0.84 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.84 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.84 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.84 |
| ▸ | ABL1 | P00519 | 1/20 | 0.84 |
| ▸ | INSR | P06213 | 1/20 | 0.84 |
| ▸ | LCK | P06239 | 1/20 | 0.84 |
| ▸ | FYN | P06241 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204366 | 1.00 | EGFR (1.00) | EGFRERBB2STK25MAP2K7CHEK1 | |
| Fumaric Acid SCHEMBL4963994 | 0.98 | EGFR (0.96) | EGFRERBB2STK25MAP2K7CHEK1 | |
| Maleic Acid SCHEMBL4963951 | 0.98 | EGFR (0.96) | EGFRERBB2STK25MAP2K7CHEK1 | |
| Hki-357 SCHEMBL29351355 | 0.93 | EGFR (1.00) | EGFRERBB2STK25MAP2K7CHEK1 | |
| Hki-357 SCHEMBL29478857 | 0.93 | EGFR (1.00) | EGFRERBB2STK25MAP2K7CHEK1 | |
| Hki-357 SCHEMBL2203420 | 0.93 | EGFR (1.00) | EGFRERBB2STK25MAP2K7CHEK1 | |
| Hki-357 SCHEMBL29351364 | 0.93 | EGFR (1.00) | EGFRERBB2STK25MAP2K7CHEK1 | |
| Hki-357 SCHEMBL2203413 | 0.93 | EGFR (1.00) | EGFRERBB2STK25MAP2K7CHEK1 | |
| SCHEMBL5496959 | 0.93 | EGFR (0.86) | EGFRERBB2 | |
| SCHEMBL18933488 | 0.93 | EGFR (0.87) | EGFRERBB2SRCKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319011-A1 | PROTEIN TYROSINE KINASE ENZYME INHIBITORS | WYETH (US) | 2008-12-25 | — | — | US | claimed |
| US-7399865-B2 | such as (E)-N-{4-[4-(benzyloxy)-3-chloroanilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide used as antineoplastic agents, or inhibitors of the HER-2 gene or proteins and epidermal growth factor receptor enzymes | WYETH (US) | 2008-07-15 | — | — | US | claimed |
| EP-1796727-A2 | METHOD FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | Wyeth a Corporation of the State of Delaware (US) | 2007-06-20 | — | — | EP | claimed |
| EP-1670473-A1 | SUBSTITUTED QUINOLINES AS PROTEIN TYROSINE KINASE ENZYME INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2006-06-21 | — | — | EP | claimed |
| WO-2006042100-A2 | METHOD FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | WYETH (US) | 2006-04-20 | — | — | WO | claimed |
| US-20060079515-A1 | Method for the treatment of polycystic kidney disease | WYETH (US) | 2006-04-13 | — | — | US | claimed |
| WO-2005034955-A1 | SUBSTITUTED QUINOLINES AS PROTEIN TYROSINE KINASE ENZYME INHIBITORS | WYETH (US) | 2005-04-21 | — | — | WO | claimed |
| WO-2005028443-A2 | PROTEIN TYROSINE KINASE ENZYME INHIBITORS | WYETH A CORPORATION OF THE STATE OF DELAWARE, USA (US) | 2005-03-31 | — | — | WO | claimed |
| US-20050059678-A1 | Protein tyrosine kinase enzyme inhibitors | WYETH (US) | 2005-03-17 | — | — | US | claimed |
| US-7982043-B2 | Protein tyrosine kinase enzyme inhibitors | WYETH LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-20080319011-A1 | PROTEIN TYROSINE KINASE ENZYME INHIBITORS | WYETH (US) | 2008-12-25 | — | — | US | disclosed |
| US-7399865-B2 | such as (E)-N-{4-[4-(benzyloxy)-3-chloroanilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide used as antineoplastic agents, or inhibitors of the HER-2 gene or proteins and epidermal growth factor receptor enzymes | WYETH (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1883631-A1 | METHODS OF SYNTHESIZING SUBSTITUTED 3-CYANOQUINOLINES AND INTERMEDIATES THEREOF | Wyeth (US) | 2008-02-06 | — | — | EP | disclosed |
| EP-1448531-B1 | 3-CYANOQUINOLINES AS INHIBITORS OF EGF-R AND HER2 KINASES | WYETH CORP (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2005028443-A2 | PROTEIN TYROSINE KINASE ENZYME INHIBITORS | WYETH A CORPORATION OF THE STATE OF DELAWARE, USA (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20050059678-A1 | Protein tyrosine kinase enzyme inhibitors | WYETH (US) | 2005-03-17 | — | — | US | disclosed |
| US-6821988-B2 | FOR USE AS ANTINEOPLASTIC AGENTS AND IN THERAPY OF POLYCYSTIC KIDNEY DISEASE | WYETH HOLDINGS CORPORATION | 2004-11-23 | — | — | US | disclosed |
| EP-1448531-A1 | 3-CYANOQUINOLINES AS INHIBITORS OF EGF-R AND HER2 KINASES | Wyeth Holdings Corporation (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20030149056-A1 | 3-cyanoquinolines as inhibitors of EGF-R and HER2 kinases | AMERICAN CYANAMID COMPANY | 2003-08-07 | — | — | US | disclosed |
| WO-2003050090-A1 | 3-CYANOQUINOLINES AS INHIBITORS OF EGF-R AND HER2 KINASES | WYETH HOLDINGS CORPORATION (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319011-A1 | PROTEIN TYROSINE KINASE ENZYME INHIBITORS | ABL1, ERBB2, RET | EGFR 6/4885ERBB2 2/4885STK25 155/4885 |
| US-20060079515-A1 | Method for the treatment of polycystic kidney disease | ERBB2, PKD2, EGFR | EGFR 3/4885ERBB2 1/4885STK25 85/4885 |
| US-20050059678-A1 | Protein tyrosine kinase enzyme inhibitors | ABL1, ERBB2, RET | EGFR 6/4885ERBB2 2/4885STK25 155/4885 |
| US-20030149056-A1 | 3-cyanoquinolines as inhibitors of EGF-R and HER2 kinases | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885STK25 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.